Affordable Access

deepdyve-link deepdyve-link
Publisher Website

The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.

Authors
  • Park, Seong Joon1
  • Ryu, Min-Hee
  • Ryoo, Baek-Yeol
  • Park, Young Soo
  • Sohn, Byeong Seok
  • Kim, Hwa Jung
  • Kim, Chan Wook
  • Kim, Ki-Hun
  • Yu, Chang Sik
  • Yook, Jeong Hwan
  • Kim, Byung Sik
  • Kang, Yoon-Koo
  • 1 Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. , (North Korea)
Type
Published Article
Journal
Annals of Surgical Oncology
Publisher
Springer - Society of Surgical Oncology
Publication Date
Dec 01, 2014
Volume
21
Issue
13
Pages
4211–4217
Identifiers
DOI: 10.1245/s10434-014-3866-4
PMID: 24980089
Source
Medline
License
Unknown

Abstract

Surgical resection of residual lesions after disease control with imatinib is likely to be beneficial to patients with recurrent or metastatic GISTs.

Report this publication

Statistics

Seen <100 times